Sentiment for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) institutional sentiment decreased to 1.5 in 2019 Q2. Its down -1.08, from 2.58 in 2019Q1. The ratio worsened, as 84 investment managers opened new or increased equity positions, while 56 sold and reduced equity positions in Ultragenyx Pharmaceutical Inc. The investment managers in our partner’s database now own: 57.68 million shares, up from 57.27 million shares in 2019Q1. Also, the number of investment managers holding Ultragenyx Pharmaceutical Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 20 Reduced: 36 Increased: 61 New Position: 23.
Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company has market cap of $2.47 billion. The firm is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It currently has negative earnings. The Company’s biologics product candidates also comprise recombinant human beta -glucuronidase , an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis.
The stock increased 2.94% or $1.22 during the last trading session, reaching $42.78. About 626,987 shares traded. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has declined 22.30% since December 4, 2018 and is downtrending. It has underperformed by 22.30% the S&P500.
Analysts await Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to report earnings on February, 18. They expect $-1.65 EPS, up 4.62 % or $0.08 from last year’s $-1.73 per share. After $-1.96 actual EPS reported by Ultragenyx Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts -15.82 % EPS growth.
Ecor1 Capital Llc holds 3.19% of its portfolio in Ultragenyx Pharmaceutical Inc. for 497,899 shares. Highline Capital Management L.P. owns 390,453 shares or 1.81% of their US portfolio. Moreover, First Light Asset Management Llc has 1.59% invested in the company for 180,017 shares. The Maryland-based Rock Springs Capital Management Lp has invested 1.33% in the stock. Capital Impact Advisors Llc, a Massachusetts-based fund reported 36,165 shares.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Ratings Coverage
Ratings analysis reveals 75% of Ultragenyx Pharmaceutical’s analysts are positive. Out of 4 Wall Street analysts rating Ultragenyx Pharmaceutical, 3 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $4500 while the high is $8000. The stock’s average target of $69 is 61.29% above today’s ($42.78) share price. RARE was included in 7 notes of analysts from August 2, 2019. The firm has “Overweight” rating given on Friday, August 2 by Morgan Stanley. The firm has “Outperform” rating given on Friday, August 2 by Wedbush. The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earned “Overweight” rating by Morgan Stanley on Wednesday, November 6. The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earned “Market Outperform” rating by JMP Securities on Wednesday, November 6. The firm has “Neutral” rating by Citigroup given on Thursday, November 7.
More notable recent Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) news were published by: Nasdaq.com which released: “How Much Does Netflix Need Stranger Things? – Nasdaq” on November 27, 2019, also Nasdaq.com with their article: “WisdomTree launches its first bitcoin exchange-traded product – Nasdaq” published on December 03, 2019, Nasdaq.com published: “SpaceX’s First Rideshare Customer Means Competition for Northrop – Nasdaq” on December 02, 2019. More interesting news about Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) were released by: Nasdaq.com and their article: “Sorrento (SRNE) Stock Has More Room to Run, Says Analyst – Nasdaq” published on December 03, 2019 as well as Nasdaq.com‘s news article titled: “Why Carvana Stock Climbed 18% Last Month – Nasdaq” with publication date: December 04, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.